Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Research Report 2023
Teduglutide (brand names Gattex in the US and Revestive in Europe) is a 33-membered polypeptide and glucagon-like peptide-2 (GLP-2) analog that is used for the treatment of short bowel syndrome.
According to QYResearch’s new survey, global Glucagon-like Peptide-2 (GLP-2) Agonist market is projected to reach US$ 2122.1 million in 2029, increasing from US$ 751 million in 2022, with the CAGR of 16.0% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Glucagon-like Peptide-2 (GLP-2) Agonist market research.
The Teduglutide market is primarily driven by the demand for innovative therapies to address short bowel syndrome (SBS) and improve the quality of life for affected patients. Teduglutide is a medication used to treat SBS, a condition characterized by impaired intestinal function due to surgical resection or congenital anomalies. The limited treatment options for SBS, coupled with advancements in gastrointestinal medicine and patient-centric care, contribute to market growth. Moreover, the demonstrated efficacy of Teduglutide in reducing dependence on parenteral nutrition and enhancing nutrient absorption further propels adoption. However, challenges include managing potential side effects and addressing patient access issues. Navigating regulatory approvals, optimizing treatment regimens, and ensuring long-term safety and efficacy are ongoing concerns. The market's success relies on continuous research in gastrointestinal disorders, collaborations between pharmaceutical manufacturers and gastroenterologists, and comprehensive patient education on the benefits and potential risks of Teduglutide treatment while addressing the evolving challenges associated with SBS management and treatment accessibility.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Glucagon-like Peptide-2 (GLP-2) Agonist market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
According to QYResearch’s new survey, global Glucagon-like Peptide-2 (GLP-2) Agonist market is projected to reach US$ 2122.1 million in 2029, increasing from US$ 751 million in 2022, with the CAGR of 16.0% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Glucagon-like Peptide-2 (GLP-2) Agonist market research.
The Teduglutide market is primarily driven by the demand for innovative therapies to address short bowel syndrome (SBS) and improve the quality of life for affected patients. Teduglutide is a medication used to treat SBS, a condition characterized by impaired intestinal function due to surgical resection or congenital anomalies. The limited treatment options for SBS, coupled with advancements in gastrointestinal medicine and patient-centric care, contribute to market growth. Moreover, the demonstrated efficacy of Teduglutide in reducing dependence on parenteral nutrition and enhancing nutrient absorption further propels adoption. However, challenges include managing potential side effects and addressing patient access issues. Navigating regulatory approvals, optimizing treatment regimens, and ensuring long-term safety and efficacy are ongoing concerns. The market's success relies on continuous research in gastrointestinal disorders, collaborations between pharmaceutical manufacturers and gastroenterologists, and comprehensive patient education on the benefits and potential risks of Teduglutide treatment while addressing the evolving challenges associated with SBS management and treatment accessibility.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Glucagon-like Peptide-2 (GLP-2) Agonist market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
- Takeda Pharmaceuticals
- Gattex
- Revestive
- Hospital
- Pharmacy
- Other
- North America
- United States
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Indonesia
- Thailand
- Malaysia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
1 GLUCAGON-LIKE PEPTIDE-2 (GLP-2) AGONIST MARKET OVERVIEW
1.1 Product Overview and Scope of Glucagon-like Peptide-2 (GLP-2) Agonist
1.2 Glucagon-like Peptide-2 (GLP-2) Agonist Segment by Type
1.2.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Value Comparison by Type (2023-2029)
1.2.2 Gattex
1.2.3 Revestive
1.3 Glucagon-like Peptide-2 (GLP-2) Agonist Segment by Application
1.3.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Value by Application: (2023-2029)
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Other
1.4 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size Estimates and Forecasts
1.4.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue 2018-2029
1.4.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales 2018-2029
1.4.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 GLUCAGON-LIKE PEPTIDE-2 (GLP-2) AGONIST MARKET COMPETITION BY MANUFACTURERS
2.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Manufacturers (2018-2023)
2.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Average Price by Manufacturers (2018-2023)
2.4 Global Glucagon-like Peptide-2 (GLP-2) Agonist Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Glucagon-like Peptide-2 (GLP-2) Agonist, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Glucagon-like Peptide-2 (GLP-2) Agonist, Product Type & Application
2.7 Glucagon-like Peptide-2 (GLP-2) Agonist Market Competitive Situation and Trends
2.7.1 Glucagon-like Peptide-2 (GLP-2) Agonist Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Glucagon-like Peptide-2 (GLP-2) Agonist Players Market Share by Revenue
2.7.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 GLUCAGON-LIKE PEPTIDE-2 (GLP-2) AGONIST RETROSPECTIVE MARKET SCENARIO BY REGION
3.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region: 2018-2029
3.2.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region: 2018-2023
3.2.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region: 2024-2029
3.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region: 2018-2029
3.3.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region: 2018-2023
3.3.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region: 2024-2029
3.4 North America Glucagon-like Peptide-2 (GLP-2) Agonist Market Facts & Figures by Country
3.4.1 North America Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2018-2029)
3.4.3 North America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Market Facts & Figures by Country
3.5.1 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2018-2029)
3.5.3 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Market Facts & Figures by Country
3.6.1 Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2018-2029)
3.6.3 Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Market Facts & Figures by Country
3.7.1 Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2018-2029)
3.7.3 Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Market Facts & Figures by Country
3.8.1 Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2018-2029)
3.8.3 Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 SEGMENT BY TYPE
4.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2018-2029)
4.1.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2018-2023)
4.1.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2024-2029)
4.1.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Type (2018-2029)
4.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type (2018-2029)
4.2.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type (2018-2023)
4.2.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type (2024-2029)
4.2.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Type (2018-2029)
4.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Price by Type (2018-2029)
5 SEGMENT BY APPLICATION
5.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2018-2029)
5.1.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2018-2023)
5.1.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2024-2029)
5.1.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Application (2018-2029)
5.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application (2018-2029)
5.2.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application (2018-2023)
5.2.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application (2024-2029)
5.2.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Application (2018-2029)
5.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Price by Application (2018-2029)
6 KEY COMPANIES PROFILED
6.1 Takeda Pharmaceuticals
6.1.1 Takeda Pharmaceuticals Corporation Information
6.1.2 Takeda Pharmaceuticals Description and Business Overview
6.1.3 Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Product Portfolio
6.1.5 Takeda Pharmaceuticals Recent Developments/Updates
7 INDUSTRY CHAIN AND SALES CHANNELS ANALYSIS
7.1 Glucagon-like Peptide-2 (GLP-2) Agonist Industry Chain Analysis
7.2 Glucagon-like Peptide-2 (GLP-2) Agonist Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Glucagon-like Peptide-2 (GLP-2) Agonist Production Mode & Process
7.4 Glucagon-like Peptide-2 (GLP-2) Agonist Sales and Marketing
7.4.1 Glucagon-like Peptide-2 (GLP-2) Agonist Sales Channels
7.4.2 Glucagon-like Peptide-2 (GLP-2) Agonist Distributors
7.5 Glucagon-like Peptide-2 (GLP-2) Agonist Customers
8 GLUCAGON-LIKE PEPTIDE-2 (GLP-2) AGONIST MARKET DYNAMICS
8.1 Glucagon-like Peptide-2 (GLP-2) Agonist Industry Trends
8.2 Glucagon-like Peptide-2 (GLP-2) Agonist Market Drivers
8.3 Glucagon-like Peptide-2 (GLP-2) Agonist Market Challenges
8.4 Glucagon-like Peptide-2 (GLP-2) Agonist Market Restraints
9 RESEARCH FINDING AND CONCLUSION
10 METHODOLOGY AND DATA SOURCE
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Overview and Scope of Glucagon-like Peptide-2 (GLP-2) Agonist
1.2 Glucagon-like Peptide-2 (GLP-2) Agonist Segment by Type
1.2.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Value Comparison by Type (2023-2029)
1.2.2 Gattex
1.2.3 Revestive
1.3 Glucagon-like Peptide-2 (GLP-2) Agonist Segment by Application
1.3.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Value by Application: (2023-2029)
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Other
1.4 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size Estimates and Forecasts
1.4.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue 2018-2029
1.4.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales 2018-2029
1.4.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 GLUCAGON-LIKE PEPTIDE-2 (GLP-2) AGONIST MARKET COMPETITION BY MANUFACTURERS
2.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Manufacturers (2018-2023)
2.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Average Price by Manufacturers (2018-2023)
2.4 Global Glucagon-like Peptide-2 (GLP-2) Agonist Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Glucagon-like Peptide-2 (GLP-2) Agonist, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Glucagon-like Peptide-2 (GLP-2) Agonist, Product Type & Application
2.7 Glucagon-like Peptide-2 (GLP-2) Agonist Market Competitive Situation and Trends
2.7.1 Glucagon-like Peptide-2 (GLP-2) Agonist Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Glucagon-like Peptide-2 (GLP-2) Agonist Players Market Share by Revenue
2.7.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 GLUCAGON-LIKE PEPTIDE-2 (GLP-2) AGONIST RETROSPECTIVE MARKET SCENARIO BY REGION
3.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region: 2018-2029
3.2.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region: 2018-2023
3.2.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region: 2024-2029
3.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region: 2018-2029
3.3.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region: 2018-2023
3.3.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region: 2024-2029
3.4 North America Glucagon-like Peptide-2 (GLP-2) Agonist Market Facts & Figures by Country
3.4.1 North America Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2018-2029)
3.4.3 North America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Market Facts & Figures by Country
3.5.1 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2018-2029)
3.5.3 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Market Facts & Figures by Country
3.6.1 Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2018-2029)
3.6.3 Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Market Facts & Figures by Country
3.7.1 Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2018-2029)
3.7.3 Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Market Facts & Figures by Country
3.8.1 Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2018-2029)
3.8.3 Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 SEGMENT BY TYPE
4.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2018-2029)
4.1.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2018-2023)
4.1.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2024-2029)
4.1.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Type (2018-2029)
4.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type (2018-2029)
4.2.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type (2018-2023)
4.2.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type (2024-2029)
4.2.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Type (2018-2029)
4.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Price by Type (2018-2029)
5 SEGMENT BY APPLICATION
5.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2018-2029)
5.1.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2018-2023)
5.1.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2024-2029)
5.1.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Application (2018-2029)
5.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application (2018-2029)
5.2.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application (2018-2023)
5.2.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application (2024-2029)
5.2.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Application (2018-2029)
5.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Price by Application (2018-2029)
6 KEY COMPANIES PROFILED
6.1 Takeda Pharmaceuticals
6.1.1 Takeda Pharmaceuticals Corporation Information
6.1.2 Takeda Pharmaceuticals Description and Business Overview
6.1.3 Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Product Portfolio
6.1.5 Takeda Pharmaceuticals Recent Developments/Updates
7 INDUSTRY CHAIN AND SALES CHANNELS ANALYSIS
7.1 Glucagon-like Peptide-2 (GLP-2) Agonist Industry Chain Analysis
7.2 Glucagon-like Peptide-2 (GLP-2) Agonist Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Glucagon-like Peptide-2 (GLP-2) Agonist Production Mode & Process
7.4 Glucagon-like Peptide-2 (GLP-2) Agonist Sales and Marketing
7.4.1 Glucagon-like Peptide-2 (GLP-2) Agonist Sales Channels
7.4.2 Glucagon-like Peptide-2 (GLP-2) Agonist Distributors
7.5 Glucagon-like Peptide-2 (GLP-2) Agonist Customers
8 GLUCAGON-LIKE PEPTIDE-2 (GLP-2) AGONIST MARKET DYNAMICS
8.1 Glucagon-like Peptide-2 (GLP-2) Agonist Industry Trends
8.2 Glucagon-like Peptide-2 (GLP-2) Agonist Market Drivers
8.3 Glucagon-like Peptide-2 (GLP-2) Agonist Market Challenges
8.4 Glucagon-like Peptide-2 (GLP-2) Agonist Market Restraints
9 RESEARCH FINDING AND CONCLUSION
10 METHODOLOGY AND DATA SOURCE
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
LIST OF TABLES
Table 1. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Value Comparison by Type (2023-2029) & (US$ Million)
Table 2. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Value Comparison by Application (2023-2029) & (US$ Million)
Table 3. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Competitive Situation by Manufacturers in 2022
Table 4. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales (K Units) of Key Manufacturers (2018-2023)
Table 5. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Manufacturers (2018-2023)
Table 6. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market Glucagon-like Peptide-2 (GLP-2) Agonist Average Price (USD/Unit) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of Glucagon-like Peptide-2 (GLP-2) Agonist, Industry Ranking, 2021 VS 2022 VS 2023
Table 10. Global Key Manufacturers of Glucagon-like Peptide-2 (GLP-2) Agonist, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Glucagon-like Peptide-2 (GLP-2) Agonist, Product Type & Application
Table 12. Global Key Manufacturers of Glucagon-like Peptide-2 (GLP-2) Agonist, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Glucagon-like Peptide-2 (GLP-2) Agonist by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Glucagon-like Peptide-2 (GLP-2) Agonist as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region (2018-2023) & (K Units)
Table 18. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Region (2018-2023)
Table 19. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region (2024-2029) & (K Units)
Table 20. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Region (2024-2029)
Table 21. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Region (2018-2023)
Table 23. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Region (2024-2029)
Table 25. North America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2018-2023) & (K Units)
Table 27. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2024-2029) & (K Units)
Table 28. North America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2018-2023) & (K Units)
Table 32. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2024-2029) & (K Units)
Table 33. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region (2018-2023) & (K Units)
Table 37. Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2018-2023) & (K Units)
Table 42. Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2024-2029) & (K Units)
Table 43. Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2018-2023) & (K Units)
Table 47. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales (K Units) by Type (2018-2023)
Table 51. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales (K Units) by Type (2024-2029)
Table 52. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Type (2018-2023)
Table 53. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Type (2024-2029)
Table 54. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (US$ Million) by Type (2018-2023)
Table 55. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Type (2018-2023)
Table 57. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Type (2024-2029)
Table 58. Global Glucagon-like Peptide-2 (GLP-2) Agonist Price (USD/Unit) by Type (2018-2023)
Table 59. Global Glucagon-like Peptide-2 (GLP-2) Agonist Price (USD/Unit) by Type (2024-2029)
Table 60. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales (K Units) by Application (2018-2023)
Table 61. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales (K Units) by Application (2024-2029)
Table 62. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Application (2018-2023)
Table 63. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Application (2024-2029)
Table 64. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (US$ Million) by Application (2018-2023)
Table 65. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Application (2018-2023)
Table 67. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Application (2024-2029)
Table 68. Global Glucagon-like Peptide-2 (GLP-2) Agonist Price (USD/Unit) by Application (2018-2023)
Table 69. Global Glucagon-like Peptide-2 (GLP-2) Agonist Price (USD/Unit) by Application (2024-2029)
Table 70. Takeda Pharmaceuticals Corporation Information
Table 71. Takeda Pharmaceuticals Description and Business Overview
Table 72. Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 73. Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Product
Table 74. Takeda Pharmaceuticals Recent Developments/Updates
Table 75. Key Raw Materials Lists
Table 76. Raw Materials Key Suppliers Lists
Table 77. Glucagon-like Peptide-2 (GLP-2) Agonist Distributors List
Table 78. Glucagon-like Peptide-2 (GLP-2) Agonist Customers List
Table 79. Glucagon-like Peptide-2 (GLP-2) Agonist Market Trends
Table 80. Glucagon-like Peptide-2 (GLP-2) Agonist Market Drivers
Table 81. Glucagon-like Peptide-2 (GLP-2) Agonist Market Challenges
Table 82. Glucagon-like Peptide-2 (GLP-2) Agonist Market Restraints
Table 83. Research Programs/Design for This Report
Table 84. Key Data Information from Secondary Sources
Table 85. Key Data Information from Primary Sources
Table 1. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Value Comparison by Type (2023-2029) & (US$ Million)
Table 2. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Value Comparison by Application (2023-2029) & (US$ Million)
Table 3. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Competitive Situation by Manufacturers in 2022
Table 4. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales (K Units) of Key Manufacturers (2018-2023)
Table 5. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Manufacturers (2018-2023)
Table 6. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market Glucagon-like Peptide-2 (GLP-2) Agonist Average Price (USD/Unit) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of Glucagon-like Peptide-2 (GLP-2) Agonist, Industry Ranking, 2021 VS 2022 VS 2023
Table 10. Global Key Manufacturers of Glucagon-like Peptide-2 (GLP-2) Agonist, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Glucagon-like Peptide-2 (GLP-2) Agonist, Product Type & Application
Table 12. Global Key Manufacturers of Glucagon-like Peptide-2 (GLP-2) Agonist, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Glucagon-like Peptide-2 (GLP-2) Agonist by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Glucagon-like Peptide-2 (GLP-2) Agonist as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region (2018-2023) & (K Units)
Table 18. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Region (2018-2023)
Table 19. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region (2024-2029) & (K Units)
Table 20. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Region (2024-2029)
Table 21. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Region (2018-2023)
Table 23. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Region (2024-2029)
Table 25. North America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2018-2023) & (K Units)
Table 27. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2024-2029) & (K Units)
Table 28. North America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2018-2023) & (K Units)
Table 32. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2024-2029) & (K Units)
Table 33. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region (2018-2023) & (K Units)
Table 37. Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2018-2023) & (K Units)
Table 42. Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2024-2029) & (K Units)
Table 43. Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2018-2023) & (K Units)
Table 47. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales (K Units) by Type (2018-2023)
Table 51. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales (K Units) by Type (2024-2029)
Table 52. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Type (2018-2023)
Table 53. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Type (2024-2029)
Table 54. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (US$ Million) by Type (2018-2023)
Table 55. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Type (2018-2023)
Table 57. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Type (2024-2029)
Table 58. Global Glucagon-like Peptide-2 (GLP-2) Agonist Price (USD/Unit) by Type (2018-2023)
Table 59. Global Glucagon-like Peptide-2 (GLP-2) Agonist Price (USD/Unit) by Type (2024-2029)
Table 60. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales (K Units) by Application (2018-2023)
Table 61. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales (K Units) by Application (2024-2029)
Table 62. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Application (2018-2023)
Table 63. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Application (2024-2029)
Table 64. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (US$ Million) by Application (2018-2023)
Table 65. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Application (2018-2023)
Table 67. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Application (2024-2029)
Table 68. Global Glucagon-like Peptide-2 (GLP-2) Agonist Price (USD/Unit) by Application (2018-2023)
Table 69. Global Glucagon-like Peptide-2 (GLP-2) Agonist Price (USD/Unit) by Application (2024-2029)
Table 70. Takeda Pharmaceuticals Corporation Information
Table 71. Takeda Pharmaceuticals Description and Business Overview
Table 72. Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 73. Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Product
Table 74. Takeda Pharmaceuticals Recent Developments/Updates
Table 75. Key Raw Materials Lists
Table 76. Raw Materials Key Suppliers Lists
Table 77. Glucagon-like Peptide-2 (GLP-2) Agonist Distributors List
Table 78. Glucagon-like Peptide-2 (GLP-2) Agonist Customers List
Table 79. Glucagon-like Peptide-2 (GLP-2) Agonist Market Trends
Table 80. Glucagon-like Peptide-2 (GLP-2) Agonist Market Drivers
Table 81. Glucagon-like Peptide-2 (GLP-2) Agonist Market Challenges
Table 82. Glucagon-like Peptide-2 (GLP-2) Agonist Market Restraints
Table 83. Research Programs/Design for This Report
Table 84. Key Data Information from Secondary Sources
Table 85. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Product Picture of Glucagon-like Peptide-2 (GLP-2) Agonist
Figure 2. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Value Comparison by Type (2023-2029) & (US$ Million)
Figure 3. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Share by Type in 2022 & 2029
Figure 4. Gattex Product Picture
Figure 5. Revestive Product Picture
Figure 6. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Value Comparison by Application (2023-2029) & (US$ Million)
Figure 7. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Share by Application in 2022 & 2029
Figure 8. Hospital
Figure 9. Pharmacy
Figure 10. Other
Figure 11. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 12. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size (2018-2029) & (US$ Million)
Figure 13. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales (2018-2029) & (K Units)
Figure 14. Global Glucagon-like Peptide-2 (GLP-2) Agonist Average Price (USD/Unit) & (2018-2029)
Figure 15. Glucagon-like Peptide-2 (GLP-2) Agonist Report Years Considered
Figure 16. Glucagon-like Peptide-2 (GLP-2) Agonist Sales Share by Manufacturers in 2022
Figure 17. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Share by Manufacturers in 2022
Figure 18. The Global 5 and 10 Largest Glucagon-like Peptide-2 (GLP-2) Agonist Players: Market Share by Revenue in 2022
Figure 19. Glucagon-like Peptide-2 (GLP-2) Agonist Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 20. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 21. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Country (2018-2029)
Figure 22. North America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Country (2018-2029)
Figure 23. United States Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 24. Canada Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 25. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Country (2018-2029)
Figure 26. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Country (2018-2029)
Figure 27. Germany Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 28. France Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 29. U.K. Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. Italy Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. Russia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Region (2018-2029)
Figure 33. Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Region (2018-2029)
Figure 34. China Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 35. Japan Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. South Korea Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. India Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. Australia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. China Taiwan Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. Indonesia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Thailand Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Malaysia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Country (2018-2029)
Figure 44. Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Country (2018-2029)
Figure 45. Mexico Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 46. Brazil Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Argentina Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Country (2018-2029)
Figure 49. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Country (2018-2029)
Figure 50. Turkey Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 51. Saudi Arabia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 52. UAE Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. Global Sales Market Share of Glucagon-like Peptide-2 (GLP-2) Agonist by Type (2018-2029)
Figure 54. Global Revenue Market Share of Glucagon-like Peptide-2 (GLP-2) Agonist by Type (2018-2029)
Figure 55. Global Glucagon-like Peptide-2 (GLP-2) Agonist Price (USD/Unit) by Type (2018-2029)
Figure 56. Global Sales Market Share of Glucagon-like Peptide-2 (GLP-2) Agonist by Application (2018-2029)
Figure 57. Global Revenue Market Share of Glucagon-like Peptide-2 (GLP-2) Agonist by Application (2018-2029)
Figure 58. Global Glucagon-like Peptide-2 (GLP-2) Agonist Price (USD/Unit) by Application (2018-2029)
Figure 59. Glucagon-like Peptide-2 (GLP-2) Agonist Value Chain
Figure 60. Glucagon-like Peptide-2 (GLP-2) Agonist Production Process
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Distributors Profiles
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Figure 1. Product Picture of Glucagon-like Peptide-2 (GLP-2) Agonist
Figure 2. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Value Comparison by Type (2023-2029) & (US$ Million)
Figure 3. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Share by Type in 2022 & 2029
Figure 4. Gattex Product Picture
Figure 5. Revestive Product Picture
Figure 6. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Value Comparison by Application (2023-2029) & (US$ Million)
Figure 7. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Share by Application in 2022 & 2029
Figure 8. Hospital
Figure 9. Pharmacy
Figure 10. Other
Figure 11. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 12. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size (2018-2029) & (US$ Million)
Figure 13. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales (2018-2029) & (K Units)
Figure 14. Global Glucagon-like Peptide-2 (GLP-2) Agonist Average Price (USD/Unit) & (2018-2029)
Figure 15. Glucagon-like Peptide-2 (GLP-2) Agonist Report Years Considered
Figure 16. Glucagon-like Peptide-2 (GLP-2) Agonist Sales Share by Manufacturers in 2022
Figure 17. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Share by Manufacturers in 2022
Figure 18. The Global 5 and 10 Largest Glucagon-like Peptide-2 (GLP-2) Agonist Players: Market Share by Revenue in 2022
Figure 19. Glucagon-like Peptide-2 (GLP-2) Agonist Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 20. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 21. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Country (2018-2029)
Figure 22. North America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Country (2018-2029)
Figure 23. United States Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 24. Canada Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 25. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Country (2018-2029)
Figure 26. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Country (2018-2029)
Figure 27. Germany Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 28. France Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 29. U.K. Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. Italy Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. Russia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Region (2018-2029)
Figure 33. Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Region (2018-2029)
Figure 34. China Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 35. Japan Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. South Korea Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. India Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. Australia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. China Taiwan Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. Indonesia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Thailand Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Malaysia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Country (2018-2029)
Figure 44. Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Country (2018-2029)
Figure 45. Mexico Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 46. Brazil Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Argentina Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Country (2018-2029)
Figure 49. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Country (2018-2029)
Figure 50. Turkey Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 51. Saudi Arabia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 52. UAE Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. Global Sales Market Share of Glucagon-like Peptide-2 (GLP-2) Agonist by Type (2018-2029)
Figure 54. Global Revenue Market Share of Glucagon-like Peptide-2 (GLP-2) Agonist by Type (2018-2029)
Figure 55. Global Glucagon-like Peptide-2 (GLP-2) Agonist Price (USD/Unit) by Type (2018-2029)
Figure 56. Global Sales Market Share of Glucagon-like Peptide-2 (GLP-2) Agonist by Application (2018-2029)
Figure 57. Global Revenue Market Share of Glucagon-like Peptide-2 (GLP-2) Agonist by Application (2018-2029)
Figure 58. Global Glucagon-like Peptide-2 (GLP-2) Agonist Price (USD/Unit) by Application (2018-2029)
Figure 59. Glucagon-like Peptide-2 (GLP-2) Agonist Value Chain
Figure 60. Glucagon-like Peptide-2 (GLP-2) Agonist Production Process
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Distributors Profiles
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
